- Beamtree (BMT) secures its first NHS (National Health Service) contracts worth about $540,000 in combined annual revenue with four hospital trusts in England
- The contracts represent the first international clients for the company’s RippleDown decision support technology as well as the first time its coding and analytic services have been used in England
- Beamtree says applications of the RippleDown technology and data analytics at the UK hospitals will include automating the coding of clinical records as well as a trial implementation to automate clinical documentation such as discharge summaries
- The company expects the initial contracts will lead to multi-year agreements and hopes to spread its services into Europe, the Middle East, the US and Asia via similar international partnerships
- BMT shares up 3.03 per cent to 34 cents
Beamtree (BMT) has nailed down its first NHS (National Health Service) contracts worth about $540,000 in combined annual revenue with four hospital trusts in England.
The company said the NHS trusts were the first international clients for its proprietary RippleDown decision support technology in hospital-based care.
Beamtree said it was already an international market leader in applications of decision support in pathology.
The company expects the initial contracts will lead to multi-year agreements and hopes to spread its services into Europe, the Middle East, the US and Asia via similar international partnerships.
“It is a great privilege to serve these leading NHS providers to support ‘Learning Health Systems’ using our products to tackle medical errors, reduce hospital acquired complications, address health access inequalities and improve efficiency,” Beamtree CEO Tim Kelsey said.
“We believe the deployment of AI and machine learning tools can make a positive impact on critical factors, such as length of patient stay in hospital and the risk of deterioration.”
Applications of Beamtree’s RippleDown technology and data analytics at the UK hospitals will include automating the coding of clinical records as well as a trial implementation to automate clinical documentation such as discharge summaries.
BMT shares ended the day’s trading session 3.03 per cent higher at 34 cents.